Angom Ramcharan S. Angom, Ph.D.

Location

Contact

SUMMARY

Angom Ramcharan S. Angom, Ph.D., researches several interrelated areas broadly linked to vascular dysfunction and remodeling. These areas include cardiovascular and cerebrovascular conditions. Dr. Angom is interested in the function of vascular endothelial growth factor (VEGF) receptors (VEGFR-1) and neuropilin (NRP-1) signaling in heart regeneration, aging and stroke.

Focus areas

• Endothelial cell dysfunction in aging. Dr. Angom uses genetically engineered zebrafish and mouse models to investigate VEGF signaling that regulates vascular remodeling in cerebrovascular disease models. He studies the role of key mediators in brain endothelial cells, which mediate inflammatory response, vascular permeability and senescence. Dr. Angom's research aims to provide mechanistic insight regarding the vascular endothelial growth factor receptor-1 signaling in brain endothelial cell senescence induction.
• VEGF-B/NRP-1/VEGFR-1 axis in myocardial infarction. This research strives to clarify the role of VEGF-B and its receptor signaling pathway in the pathogenesis of heart failure. Dr. Angom's specific research goal is to investigate the molecular mechanisms underlying VEGF-B/NRP-1/VEGFR-1 signaling in cardiac homeostasis and dysfunction. He characterizes the effect of dysregulated VEGF-B/NRP-1/VEGFR-1 signaling on cardiac structure and function, and evaluates the therapeutic potential of modulating this pathway in mitigating heart failure progression.
• VEGF-B/NRP-1 axis in cardiac hypertrophy. This research elucidates the complex signaling process of VEGF-B and NRP-1 in promoting positive cardiac remodeling in cardiovascular conditions. The main goal is to reveal the role of cardiomyocyte specific VEGF-B/NRP-1 signaling in pathological cardiac remodeling in hypertrophic cardiomyopathy and cardioprotection.
• Therapeutic intervention in glioblastomas. This research focuses on developing effective therapy to overcome medicine and radiation resistance in glioblastomas by using new tumor-targeted liposome-loaded medicine in combination with radiotherapy that may improve patient survival with minimal or no side effects.
• NRP-1 in sex-specific difference in glioblastoma. Sex differences in the incidence and outcome of glioblastomas are not sufficiently understood. The sex-specific analyses of the role of NRP-1 may improve the understanding about the molecular mechanisms linked to treatment outcomes.

Significance to patient care

Dr. Angom studies the clinical challenges of treating people with heart failure, vascular dementia and medicine resistance in glioblastomas. Findings from Dr. Angom's studies provide insights for developing new diagnostic tools, prevention methods and therapeutic plans for these individuals.

Professional highlights

• Associate editor, Frontiers in Pharmacology, 2023-present.
• Editor, Cancer Report, 2023-present.
• Guest editor, Frontiers in Neuro-Oncology, 2023-present.
• Innovation in Aging Award, Mayo Clinic, 2024-2025.
• Ted and Loretta Rogers Cardiovascular Career Development Award Honoring Hugh C. Smith, M.D., Mayo Clinic Alumni Association, 2023-2024.
• Guest editor, International Journal of Environmental Research and Public Health, 2021-2023.
• Senior research fellowship, Indian Council of Medical Research, 2012-2015.